Table 2 Study population details.

From: Modulation of intestinal TLR4 expression in infants with neonatal opioid withdrawal syndrome

Group

Maternal Age (Years)

Gestational Age(Weeks)

Birth Weight (kg)

Sex

Maternal Utox Results

Cord Tox Results

In Utero Opioid Exposure

NOWS Treatment

Age of Initial NOWS Treatment (Days)

Age at First Stool Collection (Days)

Age at Second Stool Collection (Days)

Control

           
 

23

38 6/7

3.0

Male

Negative

N/A

None

None

N/A

2

4

 

23

36 2/7

2.9

Female

THC

N/A

None

None

N/A

2

8

 

25

37 4/7

2.8

Female

Negative

N/A

None

None

N/A

2

4

 

26

36 2/7

3.4

Female

Negative

N/A

None

None

N/A

3

5

 

28

40 0/7

3.1

Female

Negative

N/A

None

None

N/A

2

5

 

31

37 5/7

3.0

Female

Negative

N/A

None

None

N/A

2

5

 

27

39 0/7

2.8

Female

Negative

N/A

None

None

N/A

1

7

 

28

37 0/7

4.0

Male

Negative

N/A

None

None

N/A

1

4

Opioid-Exposed

           
 

29

39 1/7

3.4

Female

Buprenorphine

Negative

Buprenorphine

Methadone, Clonidine

3

2

7

 

33

39 2/7

4.0

Male

Buprenorphine, TCA

Buprenorphine

Buprenorphine

Methadone, Clonidine

4

2

6

 

36

37 5/7

2.4

Female

Buprenorphine, TCAa

Fentanyl, Opiates, Morphine

Buprenorphine

Methadone

2

3

8

 

25

39 3/7

2.7

Female

Methadone

Methadone

Methadone

Methadone, Clonidine, Phenobarbital

1

2

5

 

28

39 6/7

3.6

Male

Buprenorphine

Buprenorphine

Buprenorphine

Methadone

1

2

5

 

24

40 0/7

3.5

Male

Buprenorphine, THC, TCA

Buprenorphine, THC

Buprenorphine

Methadone, Clonidine

3

2

4

 

27

38 3/7

2.8

Male

Buprenorphine

N/A

Buprenorphine

Methadone, Clonidine

1

1

6

 

36

39 0/7

2.8

Female

Methadone, TCA

Methadone, Cocaine

Methadone, Heroin

Methadone

3

2

9

 

39

39 1/7

3.2

Female

Buprenorphine, THC

Buprenorphine, THC

Buprenorphine

None

N/A

2

6

  1. The specific characteristics of mothers and infants enrolled in this study are provided for the control and opioid-exposed groups.
  2. THC tetrahydrocannabinol, TCA+ suspected cross-reactivity with Flexeril or Vistaril, N/A not applicable.
  3. aUnable to test for fentanyl due to reagent shortage.